Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Market Cap	220.35B
Revenue (ttm)	14.45B
Net Income (ttm)	5.24B
Shares Out	5.95B
EPS (ttm)	0.88
PE Ratio	42.05
Forward PE	42.96
Dividend	0.34 (0.90%)
Ex-Dividend Date	Jul 3, 2025

Volume	8,141,276
Average Volume	11,635,544
Open	38.34
Previous Close	37.06
Day's Range	36.50 - 39.14
52-Week Range	15.96 - 39.14
Beta	0.63
RSI	61.87
Earnings Date	Aug 26, 2025

About HKG:3692

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 8,989
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3692

Financial Performance

In 2024, HKG:3692's revenue was 12.26 billion, an increase of 21.35% compared to the previous year's 10.10 billion. Earnings were 4.37 billion, an increase of 33.39%.

Financial numbers in CNY